Insulin delivery system advancements -
With this device, the FDA created a lower-risk k pathway for integrated CGM. These integrated continuous glucose monitors will need to exceed stricter accuracy standards than earlier generations of devices. With this device, systems like the Dexcom G6 can be used as a stand-alone CGM or integrated in an AID system.
In the summer of , the FDA approved the Sensionics Eversense CGM. This is an implantable, day CGM sensor with an on-body transmitter with data transmitted to a smartphone displayed on a mobile application. For example, in the Prospective, Multicenter Evaluation of the Accuracy of a Novel Continuous Implanted Glucose Sensor PRECISE II trial, the overall mean absolute relative difference was 8.
Finally, the Medtronic Guardian Connect was approved, which is an adjunctive RT-CGM device that requires twice-daily calibrations. It uses the Guardian Sensor 3 and is approved for individuals 14 to 75 years old. The system alerts the user if the glucose level is 10 to 60 minutes away from a high or a low level as programmed by the user.
Table 2 provides a comparison of the characteristics of CGMs currently available [ 41 ]. See [ 41 ]. Diabetes technology continues to evolve rapidly.
In particular, the FDA creation of a new Class II pathway for continuous glucose monitors that have interconnectivity with other devices opens the door to intraoperability and accelerated development of new functionality. This means that more tools will be available to help our patients with diabetes.
However, clinical trials data will always lag behind technology development and many providers, particularly those in primary care, are not yet familiar with their use. Therefore, those familiar with the use of these devices need to be leaders in terms of educating and guiding providers and patients who have not yet been introduced to these tools.
These devices have great potential to help our patients live better with diabetes, as long as they are provided in the context of health care settings with the resources to train, educate, and follow patients using this technology.
Disclosure Summary: A. received compensation for consulting from Abbott Diabetes Care, Bigfoot, and BD; and the donation of CGM systems for research from Dexcom.
received compensation for consulting from Dexcom and research support from Medtronic Diabetes. has received compensation for consulting from Abbott Diabetes Care, Roche, Bigfoot, and BD; and research support from Medtronic Diabetes.
The remaining author has nothing to declare. Peters AL , Ahmann AJ, Battelino T, Evert A, Hirsch IB, Murad MH, Winter WE, Wolpert H. Diabetes technology—continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: an Endocrine Society Clinical Practice Guideline.
J Clin Endocrinol Metab. Google Scholar. Klonoff DC , Buckingham B , Christiansen JS , Montori VM , Tamborlane WV , Vigersky RA , Wolpert H ; Endocrine Society.
Continuous glucose monitoring: an Endocrine Society Clinical Practice Guideline. Danne T , Bangstad HJ , Deeb L , Jarosz-Chobot P , Mungaie L , Saboo B , Urakami T , Battelino T , Hanas R ; International Society for Pediatric and Adolescent Diabetes.
ISPAD Clinical Practice Consensus Guidelines Insulin treatment in children and adolescents with diabetes. Pediatr Diabetes. Sundberg F , Barnard K , Cato A , de Beaufort C , DiMeglio LA , Dooley G , Hershey T , Hitchcock J , Jain V , Weissberg-Benchell J , Rami-Merhar B , Smart CE , Hanas R.
ISPAD Guidelines. Managing diabetes in preschool children. Sullivan-Bolyai S , Knafl K , Tamborlane W , Grey M. J Nurs Scholarsh. American Diabetes Association. Children and adolescents: Standards of Medical Care in Diabetes Diabetes Care.
Ly TT , Weinzimer SA , Maahs DM , Sherr JL , Roy A , Grosman B , Cantwell M , Kurtz N , Carria L , Messer L , von Eyben R , Buckingham BA. Automated hybrid closed-loop control with a proportional-integral-derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance.
Garg SK , Weinzimer SA , Tamborlane WV , Buckingham BA , Bode BW , Bailey TS , Brazg RL , Ilany J , Slover RH , Anderson SM , Bergenstal RM , Grosman B , Roy A , Cordero TL , Shin J , Lee SW , Kaufman FR.
Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther.
Dovc K , Macedoni M , Bratina N , Lepej D , Nimri R , Atlas E , Muller I , Kordonouri O , Biester T , Danne T , Phillip M , Battelino T. Closed-loop glucose control in young people with type 1 diabetes during and after unannounced physical activity: a randomised controlled crossover trial.
Iturralde E , Tanenbaum ML , Hanes SJ , Suttiratana SC , Ambrosino JM , Ly TT , Maahs DM , Naranjo D , Walders-Abramson N , Weinzimer SA , Buckingham BA , Hood KK. Expectations and attitudes of individuals with type 1 diabetes after using a hybrid closed loop system.
Diabetes Educ. Tanenbaum ML , Iturralde E , Hanes SJ , Suttiratana SC , Ambrosino JM , Ly TT , Maahs DM , Naranjo D , Walders-Abramson N , Weinzimer SA , Buckingham BA , Hood KK. Trust in hybrid closed loop among people with diabetes: perspectives of experienced system users [ published online ahead of print 12 July ].
J Health Psychol. Bergenstal RM , Tamborlane WV , Ahmann A , Buse JB , Dailey G , Davis SN , Joyce C , Peoples T , Perkins BA , Welsh JB , Willi SM , Wood MA ; STAR 3 Study Group.
Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. REPOSE Study Group. Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial REPOSE.
Beck RW , Riddlesworth TD , Ruedy KJ , Kollman C , Ahmann AJ , Bergenstal RM , Bhargava A , Bode BW , Haller S , Kruger DF , McGill JB , Polonsky W , Price D , Toschi E ; DIAMOND Study Group. Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring DIAMOND : a multicentre, randomised controlled trial.
Lancet Diabetes Endocrinol. Bergenstal RM , Klonoff DC , Garg SK , Bode BW , Meredith M , Slover RH , Ahmann AJ , Welsh JB , Lee SW , Kaufman FR ; ASPIRE In-Home Study Group. Threshold-based insulin-pump interruption for reduction of hypoglycemia.
Choudhary P , Olsen BS , Conget I , Welsh JB , Vorrink L , Shin JJ. Hypoglycemia prevention and user acceptance of an insulin pump system with predictive low glucose management. Zhong A , Choudhary P , McMahon C , Agrawal P , Welsh JB , Cordero TL , Kaufman FR. Effectiveness of automated insulin management features of the MiniMed ® G Sensor-Augmented Insulin Pump.
Bergenstal RM , Garg S , Weinzimer SA , Buckingham BA , Bode BW , Tamborlane WV , Kaufman FR. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes.
Buckingham BPJ , Forlenza G , Cengiz E , Pettus J , Swanson V , Li Z , Lum J , Kollman C , Beck R. PROLOG: A randomized clinical trial to assess the efficacy of predictive low glucose suspend versus sensor-augmented pump therapy in the management of type 1 diabetes.
Bailey TS , Stone JY. A novel pen-based Bluetooth-enabled insulin delivery system with insulin dose tracking and advice.
Expert Opin Drug Deliv. Laffel LM , Aleppo G , Buckingham BA , Forlenza GP , Rasbach LE , Tsalikian E , Weinzimer SA , Harris DR. A Practical approach to using trend arrows on the Dexcom G5 CGM System to manage children and adolescents with diabetes. J Endocr Soc. Buckingham B , Xing D , Weinzimer S , Fiallo-Scharer R , Kollman C , Mauras N , Tsalikian E , Tamborlane W , Wysocki T , Ruedy K , Beck R ; Diabetes Research In Children Network DirecNet Study Group.
Use of the DirecNet Applied Treatment Algorithm DATA for diabetes management with a real-time continuous glucose monitor the FreeStyle Navigator. Scheiner G. Practical CGM: Improving Patient Outcomes Through Continuous Glucose Monitoring.
Arlington, VA: American Diabetes Association; Pettus J , Edelman SV. Recommendations for using real-time continuous glucose monitoring rtCGM data for insulin adjustments in type 1 diabetes. J Diabetes Sci Technol.
Erie C , Van Name MA , Weyman K , Weinzimer SA , Finnegan J , Sikes K , Tamborlane WV , Sherr JL. Schooling diabetes: use of continuous glucose monitoring and remote monitors in the home and school settings. Lind M , Polonsky W , Hirsch IB , Heise T , Bolinder J , Dahlqvist S , Schwarz E , Ólafsdóttir AF , Frid A , Wedel H , Ahlén E , Nyström T , Hellman J.
Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. Beck RW , Riddlesworth T , Ruedy K , Ahmann A , Bergenstal R , Haller S , Kollman C , Kruger D , McGill JB , Polonsky W , Toschi E , Wolpert H , Price D ; DIAMOND Study Group.
Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial.
Riddlesworth T , Price D , Cohen N , Beck RW. Hypoglycemic event frequency and the effect of continuous glucose monitoring in adults with type 1 diabetes using multiple daily insulin injections. Diabetes Ther. Continuous glucose monitoring for hypoglycemia avoidance and glucose counterregulation in long-standing type 1 diabetes.
Aleppo G , Ruedy KJ , Riddlesworth TD , Kruger DF , Peters AL , Hirsch I , Bergenstal RM , Toschi E , Ahmann AJ , Shah VN , Rickels MR , Bode BW , Philis-Tsimikas A , Pop-Busui R , Rodriguez H , Eyth E , Bhargava A , Kollman C , Beck RW ; REPLACE-BG Study Group. REPLACE-BG: A randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes.
Beck RW , Riddlesworth TD , Ruedy K , Ahmann A , Haller S , Kruger D , McGill JB , Polonsky W , Price D , Aronoff S , Aronson R , Toschi E , Kollman C , Bergenstal R ; DIAMOND Study Group. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial.
Ann Intern Med. Vigersky RA , Fonda SJ , Chellappa M , Walker MS , Ehrhardt NM. Short- and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes. Use of a real time continuous glucose monitoring system as a motivational device for poorly controlled type 2 diabetes.
Diabetes Res Clin Pract. Bolinder J , Antuna R , Geelhoed-Duijvestijn P , Kröger J , Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial.
Haak T , Hanaire H , Ajjan R , Hermanns N , Riveline JP , Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial.
Use of flash glucose-sensing technology for 12 months as a replacement for blood glucose monitoring in insulin-treated type 2 diabetes. Reddy M , Jugnee N , El Laboudi A , Spanudakis E , Anantharaja S , Oliver N. A randomized controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with type 1 diabetes and impaired awareness of hypoglycaemia.
Diabet Med. Aleppo G , Laffel LM , Ahmann AJ , Hirsch IB , Kruger DF , Peters A , Weinstock RS , Harris DR. A practical approach to using trend arrows on the Dexcom G5 CGM System for the management of adults with diabetes.
Continuous glucose monitoring in pregnant women with type 1 diabetes CONCEPTT : a multicentre international randomised controlled trial.
Christiansen MP , Klaff LJ , Brazg R , Chang AR , Levy CJ , Lam D , Denham DS , Atiee G , Bode BW , Walters SJ , Kelley L , Bailey TS.
Click Here to Manage Email Alerts. Click Here to Manage Email Alerts Back to Healio. We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice slackinc.
Back to Healio. George Grunberger. Published by:. Disclosures: Grunberger reports he receives speaking or research fees from AstraZeneca, Eli Lilly, Medtronic and Novo Nordisk. Read more about insulin. artificial pancreas. Facebook Twitter LinkedIn Email Print Comment. Related Content.
Please refresh your browser and try again. If this error persists, please contact ITSupport wyanokegroup. total views article views downloads topic views. With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area!
Find out more on how to host your own Frontiers Research Topic or contribute to one as an author. Overview Articles Authors Impact. About this Research Topic Manuscript Summary Submission Deadline 30 April Manuscript Submission Deadline 31 July Keywords : oral administration, insulin, mucus, bioavailability, oral delivery system Important Note : All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements.
Sort by: Views Type Date Views Views Type Date. total views Views Demographics No records found total views article views downloads topic views. Select a time period }. The displayed data aggregates results from Frontiers and PubMed Central®.
Expert healthcare advancemets discuss Arthritis and muscle cramps delivery methods, Insulin delivery system advancements on inhaled insulin, its pharmacological properties, and data on qdvancements control in type Insulin delivery system advancements diabetes. The panelists also talk about the advzncements of inhaled insulin in type 2 diabetes and emerging data on oral insulin. Sysfem Diana Isaacs and Advancemwnts Insulin delivery system advancements provide an overview of the types of insulin delivery systems used in type 1 diabetes T1D and type 2 diabetes T2Dincluding injections, patches, and inhalable insulin. Drs Diana Isaacs and Natalie Bellini discuss selecting the right insulin delivery method for patients with diabetes, and the challenges that arise with insulin injectables. Expert health care practitioners review the different types of insulin formulations available for people with T1D or T2D, including regular and rapid-acting. Drs Diana Isaacs and Natalie Bellini discuss the limitations of injectable insulins in achieving time-in-range and glucose targets in type 1 and type 2 diabetes. Experts examine the use of Technosphere insulin, how it is delivered to the body, and the qualities of an ideal rapid-acting insulin analog in type 1 and type 2 diabetes.Video
Omnipod® - Automated Insulin Delivery (AID) Systems Oral administration of insulin has been a longstanding goal in the advanements of diabetes management. Currently, insulin Holistic allergy treatment primarily delivered through subcutaneous injections, Insulin delivery system advancements is inconvenient and uncomfortable systek patients. However, there Insulin delivery system advancements several challenges advancemens with oral administration Insulin delivery system advancements Inxulin that need to be addressed. One major challenge is the enzymatic degradation of insulin in the gastrointestinal GI tract. The proteolytic enzymes in the stomach and small intestine can break down insulin before it can be absorbed into the bloodstream, leading to poor bioavailability. The intestinal mucus also presents a significant challenge in the oral administration of insulin. Researchers are exploring innovative strategies to address this issue, including the use of permeation enhancers, mucoadhesive formulations, and targeted drug delivery techniques.
0 thoughts on “Insulin delivery system advancements”